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The low binding affinity of D-serine 
at the ionotropic glutamate 
receptor GluD2 can be attributed to 
the hinge region
Daniel Tapken1,*, Thomas Bielefeldt Steffensen1,2,*, Rasmus Leth2, Lise Baadsgaard  
Kristensen2, Alexander Gerbola2, Michael Gajhede2, Flemming Steen Jørgensen2, Lars Olsen2 
& Jette Sandholm Kastrup2
Ionotropic glutamate receptors (iGluRs) are responsible for most of the fast excitatory communication 
between neurons in our brain. The GluD2 receptor is a puzzling member of the iGluR family: It is 
involved in synaptic plasticity, plays a role in human diseases, e.g. ataxia, binds glycine and D-serine 
with low affinity, yet no ligand has been discovered so far that can activate its ion channel. In this study, 
we show that the hinge region connecting the two subdomains of the GluD2 ligand-binding domain 
is responsible for the low affinity of D-serine, by analysing GluD2 mutants with electrophysiology, 
isothermal titration calorimetry and molecular dynamics calculations. The hinge region is highly 
variable among iGluRs and fine-tunes gating activity, suggesting that in GluD2 this region has evolved 
to only respond to micromolar concentrations of D-serine.
Ionotropic glutamate receptors (iGluRs) are present at most neurons in the central nervous system and can be 
divided into four subfamilies: α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), kainic acid 
(KA), N-methyl-D-aspartic acid (NMDA), and delta receptors1. The delta receptor subfamily comprises the 
two subunits GluD1 and GluD2, which are regarded as iGluRs based solely on sequence identity because direct 
ligand-gated ion channel function of these receptors has not been observed. However, it was recently reported 
that the metabotropic glutamate receptor mGlu1 triggers gating of GluD22.
GluD2 is predominantly expressed in the cerebellum on postsynaptic membranes at parallel fiber to Purkinje 
cell synapses and plays a critical role in long-term depression (LTD) by coordinating interactions between two 
AMPA receptor phosphorylation sites3. In the developing cerebellum, D-serine acts as an endogenous ligand 
for GluD2 to regulate LTD4. Furthermore, trans-synaptic neurexin-Cbln1-GluD2 signalling has been shown to 
induce presynaptic differentiation5–7 and synaptic plasticity7. These observations indicate that the presence of 
GluD2 is crucial in the cerebellum. Consequently, several studies have recently reported an important role in 
human disease, e.g. mevalonate kinase deficiency8 and cerebellar ataxia and atrophy9–11.
The iGluRs are homo- or heterotetrameric receptors, with each of the four subunits consisting of an 
N-terminal domain, a ligand-binding domain (LBD) comprising the two lobes D1 and D2, a membrane-spanning 
ion channel domain, and an intracellular C-terminal domain12 (Supplementary Fig. S1). Neutral amino acids such 
as D-serine and glycine can bind with low affinity (Kd ~1 mM) to a soluble construct of the GluD2 LBD, causing 
structural rearrangements in the binding cleft compared to the structure of GluD2 in its apo form13. Furthermore, 
D-serine and glycine inhibit spontaneous ion channel conductances in GluD2 containing the lurcher mutation 
(GluD2-Lc; A654T in membrane domain 3) with IC50 values of 182 μ M and 507 μ M, respectively13. A recent study 
also reports inhibition of spontaneous currents using another GluD2 mutant and suggests that it is caused by 
desensitisation14.
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Furthermore, GluD1 and GluD2 can form functional ligand-gated ion channels when harbouring the LBD of 
either an AMPA or a kainate receptor, with the GluD2 ion channel pore functioning similarly to those of AMPA 
and kainate receptors14,15. Consequently, the key differences between delta receptors and other iGluRs seem to be 
located within the LBD.
Whereas AMPA and kainate receptors are activated by glutamate binding at the LBD, the NMDA receptors 
require binding of both glutamate and glycine or D-serine to different subunits of the heteromeric complex for 
activation1. The NMDA receptor subfamily contains three glycine/D-serine-binding subunits: GluN1, GluN3A, 
and GluN3B. The GluN1 LBD binds D-serine with a Kd of 7 μ M16, GluN3A and GluN3B with even higher affinity 
(e.g. GluN3B LBD: Kd = 163 nM17). Thus, the binding affinity of D-serine at GluD2 is more than 100-fold lower 
than at NMDA receptors. The low binding affinity of D-serine at GluD2 has been a puzzle so far because the bind-
ing site residues are similar to those of other iGluRs. In this study, we have investigated this difference in binding 
affinity as well as potency for D-serine by exchanging GluD2 residues for corresponding residues from GluN1. 
By two-electrode voltage clamp electrophysiology and isothermal titration calorimetry (ITC) we show that the 
difference in potency and binding affinity can be attributed to the hinge region connecting the two lobes (D1 and 
D2) of the GluD2 LBD.
Results
Comparison of amino acid sequences between the LBDs of GluD2 and the glycine/D-serine-binding NMDA 
receptor subunit GluN1 showed an even distribution of similar residues across the whole LBD. Thus, no specific 
region in GluD2 was obvious as being responsible for the low binding affinity of D-serine. Therefore, we applied 
two strategies to investigate the reasons for the low binding affinity: i) mutation of GluD2 binding site residues 
to corresponding residues of GluN1 and ii) mutation of the D1–D2 hinge region in the GluD2 LBD to that of 
GluN1 (Fig. 1).
Unfavourable enthalpy explains the low binding affinity of D-serine at GluD2. First, we exam-
ined the characteristics of D-serine binding to soluble wild-type GluD2-LBD and GluN1-LBD in detail using 
ITC. In addition to providing binding affinities, this method allows determination of the enthalpic and entropic 
contributions to binding. We previously found that D-serine binds to GluD2-LBD with a binding affinity (Kd) of 
893 μ M in an endothermic (Δ H = 3 kcal/mol) and thus highly entropy-driven reaction (−TΔ S = − 7 kcal/mol)13 
(Table 1). By contrast, D-serine bound to the GluN1-LBD with a more than 1000-fold higher affinity of 0.7 μ M 
in an exothermic reaction that is both enthalpy- and entropy-driven (Δ H = − 3 kcal/mol, −TΔ S = − 5 kcal/mol, 
Table 1; raw data and isotherms are presented in Supplementary Fig. S2). This indicates that ligand–receptor 
interactions contribute less favourably to the binding of D-serine at GluD2-LBD than at GluN1-LBD and/or 
Figure 1. Structure of the GluD2-LBD (PDB ID 2V3U13). (a) The D1–D2 hinge region (HS1 and HS2; pink) 
as well as the positions of point mutations in the binding site generated in this study (Y496F: purple; Y543Q: 
pink; A686S: blue; Y770F: brown) are indicated. The box on the right shows a magnified view of the D1–D2 
hinge region and the D-serine binding site with all residues investigated in this study labelled. (b) Comparison 
of HS1 and HS2 residues among all 18 iGluR subunits. Residues conserved among all subunits are highlighted in 
magenta, residues conserved within subfamilies in cyan.
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that more strain is present in the GluD2 complex18. Thus, an unfavourable enthalpy can explain the low binding 
affinity of D-serine at GluD2.
Binding site mutations have moderate effects on binding affinity. To address the hypothesis 
that the differences in the amino acid residues of the binding site are responsible for the low binding affinity of 
D-serine at GluD2 compared to GluN1, residues within 4 Å of D-serine were identified for possible mutational 
analysis based on a structural alignment of the GluD2 LBD (PDB ID 2V3U) and the GluN1 LBD (PDB ID 1PB8). 
Eleven GluD2 residues were found to be within 4 Å of D-serine: Tyr496, Ala523, Leu524, Thr525, Arg530, Tyr543, 
Ser685, Ala686, Val687, Trp741, and Asp742. Of these residues, Arg530, Ser685, and Asp742 are conserved in all 
D-serine-binding iGluR subunits, and Leu524, Thr525, Val687, and Trp741 are conserved between GluD2 and 
GluN1. Thus, the four residues that are not conserved between GluD2 and GluN1 are: Tyr496, Ala523, Tyr543, 
and Ala686. Ala523 was excluded from the study because only its backbone carbonyl oxygen atom forms a hydro-
gen bond to D-serine and its side chain points away from the binding site. Instead, Tyr770, which is located 
4.3 Å from D-serine, was included. At the corresponding position, the three D-serine-binding NMDA receptor 
subunits carry a phenylalanine. Thus, the following point mutations were generated: Y496F, Y543Q, A686S, and 
Y770F (Fig. 1a, Supplementary Fig. S1).
We introduced the four GluD2 binding site mutations one at a time into the GluD2-LBD for ITC experiments 
(Table 1, raw data and isotherms are presented in Supplementary Fig. S2). The Y496F and Y543Q mutations 
had only minor effects on D-serine binding affinity (Kd of 571 μ M and 790 μ M, Table 1) compared to wild-type 
GluD2-LBD (809 μ M). The interaction of Tyr496 in GluD2 with D-serine does not involve the hydroxyl group 
of Tyr496, which may explain why the mutation to phenylalanine has little impact. The A686S mutation caused 
a slight reduction in binding affinity (Kd = 1090 μ M, Table 1). All three D-serine-binding NMDA receptor sub-
units have a serine at the corresponding position that forms a hydrogen bond with D-serine16,17. Introducing a 
serine residue into GluD2 at this position might therefore interfere in an unfavourable manner with the native 
hydrogen bonding network that involves the hydroxyl group of Tyr543 (Fig. 2a). The Y770F mutation had the 
largest impact, increasing D-serine affinity 7-fold compared to GluD2-LBD (Kd = 117 μ M vs. 809 μ M, Table 1). 
Remarkably, the mutation altered the sign of the enthalpy, making the binding exothermic (Δ H = − 2 kcal/
mol compared to 3 kcal/mol at wild-type GluD2-LBD), but at the same time reduced the favourable entropy 
(−TΔ S = − 3 kcal/mol compared to − 7 kcal/mol at wild-type GluD2-LBD).
The D1–D2 hinge from GluN1 increases D-serine binding affinity at GluD2-LBD more than 
100-fold. The LBD of GluD2, as those of all other iGluRs, has a clamshell-like structure with two lobes, D1 
and D2, closing around the ligand when it binds13,19. We defined the hinge region that changes conformation 
upon this closure based on comparison of the GluD2-LBD apo structure (PDB ID 2V3T) with the structure in 
complex with the ligand D-serine (PDB ID 2V3U; for details, see Supplementary Fig. S1). The hinge was defined 
as the following two segments: Asp542-Tyr543-Ser544 (HS1) and Val761-Gly762-Asn763-Thr764-Val765-Ala766- 
Asp767-Arg768-Gly769 (HS2) (Fig. 1, Supplementary Fig. S1). The HS1 and HS2 residues are highly variable among 
the 18 iGluR subunits, but more conserved within the subfamilies (Fig. 1b).
To analyse the impact of the D1–D2 hinge region on GluD2 function, we replaced the GluD2 hinge residues 
with the corresponding residues from GluN1 (HS1: Tyr-Gln-Gly and HS2: Thr-Gly-Glu-Leu-Phe-Phe-Arg-Ser-Gly, 
Supplementary Fig. S1). We examined the characteristics of D-serine binding to soluble GluD2-LBD-(H)GluN1 
in detail using ITC (Table 1, raw data and isotherms are presented in Supplementary Fig. S2). D-serine bound 
to GluD2-LBD-(H)GluN1 with an affinity (Kd) of 5 μ M, corresponding to a 160-fold increase compared to the 
wild-type GluD2-LBD. Just like at GluN1-LBD, binding to GluD2-LBD-(H)GluN1 was an exothermic, enthalpy- 
and entropy-driven process with Δ H = − 4 kcal/mol and −TΔ S = − 3 kcal/mol, contrary to the endothermic pro-
cess at wild-type GluD2-LBD (Table 1, Supplementary Fig. S2). Thus, the enthalpy change for D-serine binding 
shifted strongly from unfavourable to favourable, while the entropy change became somewhat less favourable 
upon transferring the hinge region from GluN1 to the GluD2-LBD. The results therefore suggest that the net 
Protein Kd (μM) ΔH (kcal/mol) −ΤΔS (kcal/mol) N na
T = 20 °C
GluD2-LBDb 893 3.1 − 7.2 1c
GluN1-LBD 0.7 ± 0.3d − 3.2 ± 0.8 − 5.0 ± 1.2 0.33 ± 0.02 3
GluD2-LBD-(H)GluN1 5.4 ± 1.7 − 4.3 ± 0.6 − 2.7 ± 0.8 0.79 ± 0.10 3
T = 25 °C
GluD2-LBD 809 ± 4 3.1 ± 0.2 − 7.13 ± 0.05 1c 3
GluD2-LBD(Y496F) 571 ± 115 1.4 ± 0.3 − 5.8 ± 0.3 1c 3
GluD2-LBD(Y543Q) 790 ± 112 0.71 ± 0.06 − 5.00 ± 0.05 1c 3
GluD2-LBD(A686S) 1090 ± 231 1.1 ± 0.1 − 5.11 ± 0.02 1c 3
GluD2-LBD(Y770F) 117 ± 11 − 2.3 ± 0.1 − 2.8 ± 0.3 1c 3
Table 1.  Thermodynamics of D-serine binding to wild-type GluD2-LBD, wild-type GluN1-LBD, the 
GluD2-LBD-(H)GluN1 hinge region mutant as well as GluD2-LBD binding site mutants determined by 
isothermal titration calorimetry. an = number of experiments. bData from Naur et al.13. cThe stoichiometry (N) 
was fixed at 1. dStandard deviation given.
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change in the number and/or strength of non-covalent interactions from the unbound to the D-serine-bound 
state is less favourable in GluD2-LBD compared to GluN1-LBD and GluD2-LBD-(H)GluN1 and/or that more 
strain is introduced in GluD2-LBD.
The D1–D2 hinge from GluN1 increases D-serine potency at GluD2 lurcher. To investigate 
whether the mutations we had studied on the isolated LBD have an effect on the function of full-length recep-
tors as well, we introduced them into the GluD2 lurcher mutant (GluD2-Lc) for electrophysiological analysis 
by two-electrode voltage clamp in Xenopus oocytes (Fig. 2, Table 2). The Y496F and Y543Q mutations had only 
minor effects on D-serine potency (IC50 of 158 μ M and 81.5 μ M, respectively; Fig. 2b,c, Table 2) compared to 
GluD2-Lc (154 μ M), matching the small changes in affinity observed at the LBD construct. The Y543Q mutation 
resulted in a slightly but significantly decreased D-serine efficacy (36%) compared to GluD2-Lc (46%) (Fig. 2d,e, 
Table 2). This might be caused by an altered hydrogen bonding network, as the hydroxyl group of Tyr543 in 
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Figure 2. Potencies and efficacies of D-serine at GluD2-Lc binding site mutants. (a) Binding site of GluD2 
(PDB ID 2V3U13) with the four residues mutated in this study shown in stick representation (Y496: purple; 
Y543: light red; A686: blue; Y770: brown). (b) Concentration–response curves for inhibition by D-serine of 
spontaneous currents mediated by GluD2-Lc and its binding site mutants determined by two-electrode voltage 
clamp electrophysiology. Each data point is shown as mean ± SEM from 8–11 oocytes. (c) Potencies of D-serine 
at GluD2-Lc and its binding site mutants displayed as IC50 values calculated from the concentration–response 
curves shown in b. Data are shown as means ± SEM from 8–11 oocytes. The significances of differences 
from GluD2-Lc were calculated for the logIC50 values by one-way ANOVA followed by Dunnett’s multiple 
comparisons test; ns, P > 0.05; ****P ≤ 0.0001. (d) Efficacies of D-serine at GluD2-Lc and its binding site 
mutants, calculated as the fraction of the spontaneous current that is inhibited by D-serine. Data are shown 
as means ± SEM from 20–30 oocytes. The significances of differences from GluD2-Lc were calculated by one-
way ANOVA followed by Dunnett’s multiple comparisons test; ns, P > 0.05; ****P ≤ 0.0001. (e) Representative 
spontaneous currents of GluD2-Lc and its binding site mutants determined by switching from Na+-free to Na+-
containing extracellular solution and their inhibition by D-serine application.
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GluD2 forms a hydrogen bond with D-serine13 (Fig. 2a). The A686S mutation caused an approximately 6-fold 
reduction in D-serine potency (1020 μ M) (Fig. 2b,c, Table 2), whereas the Y770F mutation had the largest impact, 
increasing D-serine potency approximately 8-fold compared to GluD2-Lc (IC50 = 18.5 μ M vs. 154 μ M, Fig. 2b,c, 
Table 2), a change similar to the change in affinity at the LBD construct.
As observed at the isolated GluD2-LBD, replacing the GluD2 D1–D2 hinge with that of GluN1 had by far the 
largest impact: D-serine potency at GluD2-Lc increased 130-fold, reducing the IC50 from 154 μ M at GluD2-Lc 
to 1.2 μ M at GluD2-Lc-(H)GluN1, a value virtually identical to the 1.4 μ M observed for GluN1-1a (Fig. 3a–c, 
Table 2). The concentration–response curve of GluD2-Lc-(H)GluN1 was bell-shaped, with maximum inhibition 
of spontaneous currents occurring at 10 μ M D-serine. At D-serine concentrations above the IC50, we observed 
peak and tail currents upon application and removal of the agonist, respectively (Fig. 3c,d): When applying 
D-serine, an inward peak current occurred that added to the spontaneous current of GluD2-Lc. When remov-
ing D-serine, an outward tail current was observed that further reduced the spontaneous current beyond the 
steady-state inhibition by D-serine. Moreover, the maximal, absolute, D-serine-induced steady-state inhibition 
of spontaneous currents was reduced about 4-fold for the GluD2-Lc-(H)GluN1 chimera (53 ± 8 nA, n = 30) com-
pared to GluD2-Lc (222 ± 36 nA, n = 20). This reduction was not caused by decreased spontaneous currents, 
e.g. through impaired channel function or reduced expression, as spontaneous currents of GluD2-Lc-(H)GluN1 
(385 ± 30 nA, n = 30) were not significantly different from those of GluD2-Lc (481 ± 69 nA, n = 20). Rather, the 
D1–D2 hinge region from GluN1 reduced the efficacy of D-serine at GluD2-Lc, as indicated by a reduction of 
the relative inhibition of spontaneous currents from 46% at GluD2-Lc to 13% at GluD2-Lc-(H)GluN1 (Fig. 3e,f, 
Table 2).
To further narrow down the GluN1 residues responsible for transferring the high D-serine potency to GluD2, 
we examined mutants of GluD2-Lc that contained only the GluN1 hinge residues located in S1 (HS1) or S2 (HS2), 
respectively. Mutation of the three HS1 residues had no significant effect on D-serine potency (IC50 of 129 μ M for 
GluD2-Lc-(HS1)GluN1 vs. 154 μ M for GluD2-Lc; Fig. 3a,b, Table 2), whereas the relative inhibition of spontane-
ous currents by D-serine was slightly but significantly reduced from 46% at GluD2-Lc to 29% at GluD2-Lc-(HS1)
GluN1 (Fig. 3e,f, Table 2). By contrast, introducing the eight HS2 residues from GluN1 (GluD2-Lc-(HS2)GluN1) 
almost completely abolished D-serine sensitivity of GluD2-Lc (Fig. 3e,f, Table 2). Spontaneous currents were only 
slightly reduced from 481 ± 69 nA (n = 20) to 302 ± 18 nA (n = 20), but they were hardly inhibited by D-serine 
(0.9 ± 0.4%, n = 20, Table 2). Therefore, D-serine potency at this mutant could not be determined. These results 
show that the HS1 and HS2 regions need to be replaced simultaneously to confer GluN1-like D-serine potency to 
GluD2-Lc.
To further verify this conclusion, we analysed three more mutants of GluD2-Lc that contained the HS2 region 
and additionally one of the three HS1 residues from GluN1. One of these mutants (GluD2-Lc(D542Y)-(HS2)
GluN1) remained insensitive to D-serine just like GluD2-Lc-(HS2)GluN1, whereas the other two were again 
inhibited by D-serine (Fig. 3e,f, Table 2). At both of these mutants, D-serine potency was significantly higher 
than at GluD2-Lc (15-fold for GluD2-Lc(Y543Q)-(HS2)GluN1 and 3-fold for GluD2-Lc(S544G)-(HS2)GluN1), 
yet did not come close to the 1.2 μ M of GluD2-Lc-(H)GluN1 (Fig. 3a,b, Table 2). This confirms that the full hinge 
assembly from GluN1 is needed to transfer the high D-serine potency to GluD2.
These findings raised the question whether the opposite is also possible: Can the low D-serine potency of 
GluD2-Lc be transferred to GluN1 by transferring the hinge ? We analysed the GluN1-1a-(H)GluD2 mutant using 
electrophysiology in the heteromeric combination with GluN2A and hardly observed any current response to 
100 μ M glutamate plus 1 mM D-serine (5.8 ± 1.0 nA, n = 23). While most oocytes showed currents in the range of 
the background seen in uninjected control oocytes (2.7 ± 0.2 nA, n = 23), a few had slightly higher responses, yet 
still not sufficient to record a concentration–response relationship.
Because the hinge region from GluN1 had such a strong impact on the GluD2-Lc mutant, we wondered 
whether it might render the GluD2 wild-type functional. However, this was not the case: GluD2-(H)GluN1 
Protein
IC50 (μM) [EC50 (μM) for GluN1/GluN2A]
n
D-serine efficacy (%)
nMean 95% confidence interval Mean ± SEM
GluD2-Lc 154 138–173 11 46.2 ± 1.9 30
GluN1-1a (with GluN2A) 1.35 1.26–1.45 8 n/a*
GluD2-Lc-(H)GluN1 1.19 0.84–1.69 6 12.9 ± 0.8 30
GluD2-Lc-(HS1)GluN1 129 100–165 9 29.1 ± 1.1 20
GluD2-Lc-(HS2)GluN1 n/a** n/a** 0.9 ± 0.4 20
GluD2-Lc(D542Y)-(HS2)GluN1 n/a** n/a** –3.4 ± 0.5 20
GluD2-Lc(Y543Q)-(HS2)GluN1 10.5 8.5–13.0 8 24.1 ± 0.4 20
GluD2-Lc(S544G)-(HS2)GluN1 47.9 41.4–55.6 8 40.6 ± 0.5 20
GluD2-Lc(Y496F) 158 141–176 11 43.5 ± 2.0 20
GluD2-Lc(Y543Q) 81.5 73.4–90.4 11 36.2 ± 0.6 20
GluD2-Lc(A686S) 1020 911–1143 8 43.9 ± 0.7 20
GluD2-Lc(Y770F) 18.5 17.1–20.0 8 59.9 ± 1.7 20
Table 2.  D-serine potencies (IC50 or EC50) and efficacies (%) at GluD2-Lc D1–D2 hinge region and binding 
site mutants determined by two-electrode voltage clamp electrophysiology in Xenopus oocytes. *Efficacy 
cannot be calculated for an excitatory response. **No response to D-serine.
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Figure 3. Potencies and efficacies of D-serine at GluD2-Lc D1–D2 hinge region mutants.  
(a) Concentration–response curves for inhibition by D-serine of spontaneous currents mediated by 
GluD2-Lc, its full hinge region mutant GluD2-Lc(H)GluN1, and three partial hinge region mutants that 
respond to D-serine. The concentration–response curve for activation of GluN1-1a/GluN2A by D-serine in 
the presence of 100 μ M glutamate is shown for comparison. All curves were determined by two-electrode 
voltage clamp electrophysiology. Each data point is shown as mean ± SEM from 6–11 oocytes. (b) Potencies 
of D-serine at GluD2-Lc and its full and partial hinge region mutants displayed as IC50 values calculated 
from the concentration–response curves shown in a. Data are shown as means ± SEM from 6–11 oocytes. 
The significances of differences from GluD2-Lc were calculated for the logIC50 values by one-way ANOVA 
followed by Dunnett’s multiple comparisons test; ns, P > 0.05; ****P ≤ 0.0001. (c) Current traces of GluD2-Lc 
and GluD2-Lc-(H)GluN1 upon application of various D-serine concentrations. The traces are normalized to 
the amplitude of the current induced by a saturating D-serine concentration (10 mM for GluD2-Lc, 10 μ M for 
GluD2-Lc-(H)GluN1). (d) Current traces of GluD2-Lc and GluD2-Lc-(H)GluN1 recorded at high D-serine 
concentrations. GluD2-Lc-(H)GluN1 shows peak and tail currents upon application and removal of D-serine, 
respectively. (e) Efficacies of D-serine at GluD2-Lc and its full and partial hinge region mutants, calculated as 
the fraction of the spontaneous current that is inhibited by D-serine. Data are shown as means ± SEM from 
20–30 oocytes. The significances of differences from GluD2-Lc were calculated by one-way ANOVA followed 
by Dunnett’s multiple comparisons test; **P ≤ 0.01; ****P ≤ 0.0001. (f) Representative spontaneous currents of 
GluD2-Lc and its hinge region mutants determined by switching from Na+-free to Na+-containing extracellular 
solution and their inhibition by D-serine application.
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showed barely detectable current responses upon application of 10 μ M D-serine (1.1 ± 0.6 nA, n = 14) or 1 mM 
D-serine (2.3 ± 0.4 nA, n = 22) that were in the range of currents observed on uninjected control oocytes 
(0.1 ± 0.1 nA, n = 12 at 10 μ M D-serine, 2.4 ± 0.2 nA, n = 18 at 1 mM D-serine).
Dynamics of the binding site and hinge region. In order to investigate the structural basis of 
the changes in binding and receptor function, we performed 100 ns molecular dynamics (MD) simula-
tions on GluD2-LBD, GluN1-LBD, and GluD2-LBD-(H)GluN1 in their apo and D-serine-bound states, 
respectively. All the systems were stable during the simulations, as indicated by the RMSDs on all Cα atoms 
(Supplementary Fig. S3). The total number of hydrogen bonds from binding site residues to D-serine varied only 
to a minor extent (Supplementary Fig. S4) as well as D1–D2 domain movements, as indicated by ζ 1 and ζ 2 values 
(Supplementary Fig. S5). In addition, D-serine displayed conformations in the receptors that are also observed in 
solvent, showing that the ligand was not constrained in any unusual conformations (data not shown).
During the MD simulations, a total of seven amino acid residues in GluD2-LBD (Tyr496, Ala523, Thr525, 
Arg530, Tyr543, Ala686, Asp742) and five residues in GluN1-LBD (Pro516, Thr518, Arg523, Ser688, Asp732) 
as well as water molecules were engaged in hydrogen bonding to D-serine (Supplementary Table S1, water mol-
ecules not included). Overall, the hydrogen bonding patterns from D-serine to binding site residues are similar 
in GluD2 and GluN1, supporting the observation that point mutations of binding site residues affect binding 
affinity and potency of D-serine only to a minor extent. The most pronounced differences arise from: i) the 
presence of Tyr496 in GluD2-LBD (Phe484 in GluN1-LBD) whose hydroxyl group forms hydrogen bonds to the 
ammonium group of D-serine, ii) Tyr543 in GluD2-LBD and Gln536 in GluN1-LBD, which form a direct and a 
water-mediated hydrogen bond to the hydroxyl group of D-serine, respectively, and iii) Ser688 in GluN1-LBD 
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Figure 4. Molecular dynamics simulations on GluD2-LBD, GluN1-LBD, and GluD2-LBD-(H)GluN1 
in their D-serine-bound forms. (a) Hydrogen bonds (yellow dashed lines) between D-serine (green) and 
binding site residues (sand) as well as from Asp742 to Tyr543 and Tyr770 (orange dashed lines) in GluD2-LBD. 
All hydrogen bonds to D-serine observed during the simulation have been mapped onto the X-ray structure 
(PDB ID 2V3U). (b) Hydrogen bonds between D-serine and binding site residues as well as from Gln536 to 
Asp732 and Ser756 (orange dashed lines) in GluN1-LBD. All hydrogen bonds to D-serine observed during the 
simulation have been mapped onto the X-ray structure (PDB ID 1PB8). (c) Hydrogen bonds between D-serine 
and binding site residues as well as from Gln543 to Asp742, Ser768, and Tyr770 in GluD2-LBD-(H)GluN1. All 
hydrogen bonds to D-serine observed during the simulation have been mapped onto the model structure.  
(d–f) Variation of the phi and psi torsional angles for two residues in the HS2 region during the 100 ns MD 
simulation. (d) GluD2-LBD with D-serine. (e) GluN1-LBD with D-serine. (f) GluD2-LBD-(H)GluN1 with 
D-serine. For phi and psi values of all the residues in HS2, see Supplementary Fig. S7.
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(Ala686 in GluD2-LBD) whose hydroxyl group is involved in hydrogen bonding to both the carboxylate and 
hydroxyl group of D-serine (Fig. 4a,b).
To address the effects of introducing the D1–D2 hinge region from GluN1 into GluD2, we transferred these 
residues into the GluD2-LBD apo and D-serine-bound structures and then performed 100 ns MD simula-
tions. First, we analysed the overall flexibility of the six structures. As expected, the apo structures were gener-
ally more flexible than the D-serine-bound structures (Supplementary Figs S3 and S5). Whereas flexibility was 
more pronounced in the hinge regions in GluN1-LBD and GluD2-LBD-(H)GluN1, the long HS2 hinge region in 
GluD2-LBD underwent a conformational change after 40 ns (Supplementary Figs S6 and S7). Subsequently, we 
analysed the fluctuations in backbone phi and psi angles of each HS2 residue (Supplementary Fig. S7). Large fluc-
tuations were seen in the psi angle of Gly750 in GluN1-LBD and the corresponding Gly762 in GluD2-LBD-(H)
GluN1 as well as in the phi angle of Glu751 in GluN1-LBD and Glu763 in GluD2-LBD-(H)GluN1 (Fig. 4e,f). On 
the contrary, the corresponding phi and psi angles seemed stable in GluD2-LBD (Fig. 4d). This indicates more 
backbone flexibility in the HS2 hinge region in GluN1-LBD and GluD2-LBD-(H)GluN1 than in GluD2-LBD and 
points towards structural differences between the hinge regions in GluD2 and GluN1 that might be of importance 
for determining binding affinity of D-serine.
Discussion
In summary, this study defines the D1–D2 hinge region as being responsible for the low binding affinity of 
D-serine at the ligand-binding domain of GluD2 and low potency of D-serine at the GluD2 lurcher mutant. By 
contrast, changing binding site residues by single point mutations had only minor effects on the binding affinity 
of D-serine at GluD2.
We found that replacing the hinge region that connects the two lobes of the LBD with that from the NMDA 
receptor subunit GluN1 increased affinity of D-serine at a soluble GluD2-LBD construct as well as potency of 
D-serine at the spontaneously open GluD2 lurcher mutant more than 100-fold, bringing both values close to 
those at GluN1. Whereas D-serine binding is endothermic and entropy-driven at the wild-type GluD2-LBD, the 
hinge region from GluN1 rendered it exothermic, so it became both enthalpy- and entropy-driven, as observed at 
GluN1. Furthermore, molecular dynamics simulations suggested that the conformation of the GluN1 HS2 hinge 
region is preserved when transferring it to the GluD2 LBD. The reverse experiment, replacing the hinge region of 
GluN1 with that from GluD2, produced a non-functional chimera, so D-serine potency could not be determined. 
Similar observations of non- or barely functional chimeras composed of regions or domains that are perfectly 
functional in the wild-type protein have previously been made20,21.
At the GluD2 lurcher mutant, introducing the hinge region from GluN1 not only changed D-serine potency 
but also other properties of the receptor. Application of high D-serine concentrations induced a transient inward 
peak current followed by a reduced inhibition of the spontaneous current compared to GluD2-Lc. As the inhi-
bition of spontaneous currents is likely caused by desensitisation13, these findings suggest that the GluN1 hinge 
slows and reduces desensitisation at GluD2-Lc, so an activation peak can be observed before a less pronounced 
desensitisation sets in. Another striking feature of GluD2-Lc-(H)GluN1 is its bell-shaped concentration–response 
curve, with a maximal inhibition of spontaneous currents at 10 μ M D-serine and smaller steady-state inhibition 
followed by apparently outward tail currents upon D-serine washout at higher concentrations. The tail currents 
can probably be explained by lower D-serine concentrations briefly reached during washout that induce maximal 
inhibition. Bell-shaped concentration–response curves have been reported for other glutamate receptors, e.g. in 
heteromeric assemblies such as GluN1/GluN322 and GluK2/GluK523,24 that contain binding sites with different 
agonist affinities on subunits with different gating properties or in complexes with auxiliary proteins such as 
TARPs that can dissociate from the receptor upon agonist binding25. Investigating the mechanistic reasons for 
the unusual concentration-dependent behaviour of the homomeric GluD2-Lc-(H)GluN1 will require extensive 
analysis of its gating properties.
In GluD2-Lc, the introduction of the HS1 part of the hinge from GluN1 (Tyr-Gln-Gly) alone did not have any 
effect on D-serine potency, whereas the long HS2 part alone completely abolished D-serine efficacy (Table 2). This 
illustrates that the full hinge assembly from GluN1 is needed to transfer the high D-serine potency to GluD2-Lc. 
The single most important residue in HS1 for increasing D-serine potency seems to be at position 543 in GluD2, 
where introduction of Gln instead of Tyr (GluD2-Lc(Y543Q)-(HS2)GluN1) leads to a 15-fold increased potency in 
conjunction with the HS2 residues from GluN1. The corresponding Gln536 in GluN1-LBD was observed to form 
hydrogen bonding contacts to the important D-serine-interacting residue Asp732 and the HS2 hinge region resi-
due Ser756 (Fig. 4b). Similarly, in GluD2-LBD-(H)GluN1 major contacts are seen from the new HS1 hinge residue 
Gln543 to the new HS2 hinge residue Ser768 during the MD simulation, as well as to Asp742 and Tyr770 (Fig. 4c). 
Introduction of Tyr instead of Asp542 (GluD2-Lc(D542Y)-(HS2)GluN1) did not rescue D-serine efficacy.
The hinge region is highly variable among iGluR subfamilies (Fig. 1b) and fine-tunes gating activity. For 
example, in NMDA receptors, the HS1 hinge residue Tyr535 in GluN1 (corresponding to Asp542 in GluD2) 
has been shown to control the deactivation rate of heteromeric GluN1/GluN2A receptors: mutations increasing 
hydrophobic contacts slowed deactivation, whereas mutations decreasing hydrophobic contacts accelerated it26,27. 
Therefore, it is tempting to speculate that the D1–D2 hinge region in GluD2 has evolved in a way only allowing 
the receptor to respond to micromolar concentrations of D-serine. It means that D-serine/glycine can dissoci-
ate rapidly from the receptor to terminate a response. D-serine has previously been shown to regulate LTD at 
synapses between parallel fibers and Purkinje cells in the immature cerebellum through its action as an endog-
enous ligand for GluD27. The inhibitory effect of D-serine on the parallel fiber EPSCs was shown to increase in 
a dose-dependent manner with an apparent EC50 of 147 μ M. This EC50 is in agreement with what we observe at 
GluD2-Lc (154 μ M). However, although D-serine binding to GluD2 has been demonstrated to play an important 
physiological role in regulating cerebellar LTD and motor coordination4, direct ligand-gated ion channel function 
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of GluD2 has not been observed yet. Therefore, the specific role of the hinge region for the physiological function 
of GluD2 remains elusive until the molecular mechanism of GluD2 signalling is fully understood.
In conclusion, the present study opens new perspectives for studies of the function of GluD2 and the unique 
characteristics of the D1–D2 hinge region. Future comparative studies of differences in this hinge region among 
the 18 iGluR subunits would likely provide essential information of general interest on these receptors.
Methods
GluD2-LBD constructs. The constructs for expression of wild-type rat GluD2-LBD13 and GluD2-LBD 
mutants are composed of an N-terminal extension coding for a His-tag and a trypsin cleavage site, the GluD2 S1 
residues Gly440–Arg551, a Gly-Thr linker, and GluD2 S2 residues Ser664–Leu813. Amino acid residues are num-
bered based on the full-length polypeptide sequence (GenBank accession no.: NM_024379) including the signal 
peptide of 23 residues. Mutations in GluD2-LBD were introduced using overlap extension PCR28, except for the 
GluD2-LBD-(H)GluN1 mutant, which was produced by GenScript USA Inc. (Piscataway, NJ, USA).
GluN1-LBD construct. The GluN1-LBD construct comprises an N-terminal region coding for a His-tag 
and a thrombin cleavage site, the GluN1 S1 residues Met394-Lys544, a Gly-Thr linker, and GluN1 S2 residues 
Arg663-Ser80016. Amino acid residues are numbered based on the full-length polypeptide sequence including the 
signal peptide (UniProt accession no. P35439).
Expression and purification. Wild-type GluD2-LBD and mutants were expressed in the E. coli cell line 
Origami 2 (Novagen, Madison, WI, USA) using the T7 expression vector pET28+ as previously described13. In 
brief, the protein was purified by affinity chromatography using a HisTrap FF column (GE Healthcare, Hillerød, 
Denmark). The His-tag was cleaved by trypsin digestion, leaving one N-terminal remnant Gly. The final purifica-
tion step comprised ion exchange chromatography using a HiTrap FF column (GE Healthcare). The eluted pro-
tein was then dialysed three times against ITC buffer (100 mM HEPES, 100 mM NaCl, 2 mM KCl, 10% glycerol, 
pH 7.0).
GluN1-LBD was expressed in E. coli Origami B (DE3) (Novagen) using the T7 expression vector pET22c as 
previously described29. Expression was performed in LB medium overnight at 20 °C by IPTG induction (0.1 mM). 
In brief, the protein was purified by affinity chromatography using a HisTrap FF column (GE Healthcare). The 
His-tag was cleaved overnight with thrombin (2 U/mg protein) at room temperature, which leaves one remnant 
N-terminal Gly. As a final purification step, the protein was purified by ion exchange chromatography using a 
HiTrap SP FF column (GE Healthcare). The protein buffer was exchanged to ITC buffer using dialysis (three times 
buffer exchange).
All proteins were checked for correct folding using circular dichroism (CD) spectroscopy (data not shown). In 
addition, size-exclusion chromatography confirmed that GluD2-LBD, GluN1-LBD and GluD2-LBD-(H)-GluN1 
elute in the same volume, indicating that all proteins are monomeric in solution (Supplementary Fig. S8).
GluD2 lurcher constructs. All cDNAs for expression in Xenopus oocytes were cloned into the vector 
pSGEM30. Point mutants of GluD2-Lc were constructed by overlap extension PCR with mutagenic oligonucle-
otide primers28. The GluD2-Lc-(H)GluN1 chimera was constructed by transferring the S1- and S2-encoding 
sequences from GluD2-LBD-(H)GluN1 to GluD2-Lc via overlap extension PCR using tail primers. The S1 and 
S2 sequences were transferred separately, yielding GluD2-Lc-(HS1)GluN1 and GluD2-Lc-(HS2)GluN1 constructs. 
GluD2-Lc-(H)GluN1 was then produced from these by another overlap extension PCR. Complementary RNA 
(cRNA) for injection into oocytes was synthesised from 1 μ g of linearised template DNA with the mMESSAGE 
mMACHINE in vitro transcription kit (Ambion, Austin, TX, USA).
Isothermal titration calorimetry. The concentration of the proteins in ITC buffer (100 mM HEPES, 
100 mM NaCl, 2 mM KCl, 10% glycerol, pH 7.0) was between 0.02 mM and 0.09 mM as determined by UV 
absorption. D-serine was dissolved in ITC buffer that had been used for the final round of protein dialysis to 
a concentration of 0.2 mM–21 mM, and afterwards filtered through a 0.22 μ m filter. The ITC experiments were 
carried out on either a VP-ITC calorimeter (MicroCal, GE Healthcare) or an ITC200 calorimeter (MicroCal, 
GE Healthcare) with cell volumes of 1.4 mL and 200 μ L, respectively. Experiments were performed at 25 °C for 
GluD2-LBD and GluD2-LBD binding site mutants and at 20 °C for GluN1-LBD and GluD2-LBD-(H)GluN1. The 
experiments were performed as 20 injections of D-serine into the protein solution. At the VP-ITC calorimeter 
the injection volume was 2 μ L for the first and 15 μ L for all following injections, at the ITC200 calorimeter it was 
0.2 μ L for the first and 2 μ L for all following injections. The data were analysed using Origin 7.0 (OriginLabs, 
Northampton, MA, USA) using a single binding site model31. The baseline was manually corrected for a few data 
sets and the first data point discarded.
Electrophysiology on Xenopus laevis oocytes. Oocytes were obtained by surgically removing parts 
of the ovaries from Xenopus laevis (Nasco, Fort Atkinson, WI, USA) anaesthetised with 1.5 g/L 3-aminobenzoic 
acid ethylester (Sigma, Taufkirchen, Germany). The ovary clippings were digested with 784 U/mL (4 mg/mL) 
collagenase type I (Worthington, Lakewood, NJ, USA) in Ca2+-free Barth’s solution (88 mM NaCl, 1.1 mM KCl, 
2.4 mM NaHCO3, 0.8 mM MgSO4, 15 mM HEPES-NaOH, pH 7.6) with gentle agitation for 1.5–2 h at 20 °C to 
remove the follicular cell layer. After stopping the collagenase digestion by washing with Barth’s solution (88 mM 
NaCl, 1.1 mM KCl, 2.4 mM NaHCO3, 0.3 mM Ca(NO3)2, 0.4 mM CaCl2, 0.8 mM MgSO4, 15 mM HEPES-NaOH, 
pH 7.6), defolliculated oocytes of stages V and VI were selected and maintained at 16 °C in Barth’s solution sup-
plemented with 100 μ g/mL gentamicin, 40 μ g/mL streptomycin, and 63 μ g/mL penicillin. Oocytes were injected 
with 11 ng cRNA (10 ng of each cRNA for co-expression of GluN1 and GluN2A) using a nanoliter injector (WPI, 
Sarasota, FL, USA). Four days after cRNA injection, current responses were recorded under voltage clamp at 
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–70 mV with a Turbo Tec-10CD amplifier (npi electronic, Tamm, Germany) controlled by Patchmaster software 
(HEKA, Lambrecht, Germany). Currents were filtered with a 20 Hz low-pass filter and then digitised with a sam-
pling rate of 50 Hz. Recording electrodes were pulled from borosilicate glass (Hilgenberg, Malsfeld, Germany) 
with an L/M-3P-A vertical pipette puller (List-Medical), filled with 3 M KCl, and had resistances of 0.5–5 MΩ 
(voltage electrode) or 0.5–1.5 MΩ (current electrode). Recordings were performed in a 50 μ L chamber under con-
stant superfusion with extracellular solution at a flow rate of 3–5 mL/min. The standard extracellular solution was 
Ca2+- and Mg2+-free barium normal frog Ringer’s solution (Ba-NFR; 115 mM NaCl, 2.5 mM KCl, 1.8 mM BaCl2, 
10 mM HEPES-NaOH, pH 7.2). D-serine potencies were determined by measuring steady-state current responses 
induced by the application of increasing D-serine concentrations to the same oocyte. The obtained responses 
were normalised to the maximal response induced by a saturating D-serine concentration and the normalised 
data from six to eleven oocytes averaged and fitted to the Hill equation using Prism (GraphPad, San Diego, 
CA, USA). D-serine efficacies were investigated by determining the fraction of the spontaneous current through 
GluD2-Lc channels that was inhibited by a saturating concentration of D-serine. To this end, the amplitude of the 
spontaneous current was determined by switching from a Na+-free solution containing the impermeable cation 
NMDG (NMDGR; 115 mM NMDG-Cl, 2.5 mM KCl, 1.8 mM BaCl2, 10 mM HEPES, pH 7.2) to Na+-containing 
Ba-NFR. Then D-serine in Ba-NFR was applied and the inhibition of the spontaneous current measured. Finally, 
Ba-NFR and then NMDGR were applied again to check for reversibility.
Preparation of structures for molecular dynamics simulations. Wild-type GluD2-LBD, 
GluD2-LBD-(H)GluN1, and wild-type GluN1-LBD were prepared as apo structures and with D-serine bound as 
described below.
For calculations on the wild-type GluD2 apo structure, the structure of apo GluD2-LBD (PDB ID 2V3T, 
molB) was used. The hinge region residues 763–764 are not present in the structure. These residues were built 
according to the weak electron density. Six C-terminal residues were adopted from molA. All water molecules 
within 5 Å of the protein were kept.
For wild-type GluD2 with D-serine bound, the structure of GluD2-LBD with D-serine (PDB ID 2V3U) was 
used. As loop 715–719 was not built in this structure, the loop from the GluD2-LBD apo structure (PDB ID 2V3T, 
molB, residues 713–719) was modelled in. Furthermore, hinge region residues 763–765 were not present in the 
structure. These residues were built according to the weak electron density. D-serine and all water molecules 
within 5 Å of the protein were kept.
For wild-type apo GluN1, the structure of apo GluN1-LBD (PDB ID 4KCC) was used. Loops 441–448 and 
491–495 are missing in the structure and were adopted from the structure of GluN1-LBD with ACPC (PDB ID 
1Y20, 440–449 and 490–496, respectively). Residues built as Ala were changed to corresponding residues in the 
protein sequence. Side-chain rotamers that did not provide clash with the protein and occur frequently were 
chosen. All water molecules within 5 Å of the protein were kept.
For wild-type GluN1 with D-serine bound, the structure of GluN1-LBD with D-serine (PDB ID 1PB8) was 
used. Loop 441–447 was missing in the structure and was adopted from the structure of GluN1-LBD with ACPC 
(PDB ID 1Y20, 440–448). Residues built as Ala were changed to corresponding residues in the protein sequence. 
Side-chain rotamers that did not provide clash with the protein and occur frequently were chosen. D-serine and 
all water molecules within 5 Å of the protein were kept.
For constructing the apo GluD2-LBD-(H)GluN1 mutant, GluN1 residues Tyr535, Gln536, and Gly537 were 
inserted instead of GluD2 residues Asp542, Tyr543, and Ser544 (HS1) and GluN1 residues Thr749, Gly750, 
Glu751, Leu752, Phe753, Phe754, Arg755, Ser756, and Gly757 instead of GluD2 residues Val761, Gly762, Asn763, 
Thr764, Val765, Ala766, Asp767, Arg768, and Gly769 (HS2). The side chain conformation of seven residues was 
adjusted to avoid clash with surrounding residues. One water molecule in the vicinity of the D1–D2 hinge region 
that would cause steric clash was deleted.
For constructing the GluD2-LBD-(H)GluN1 mutant with D-serine bound, GluN1 residues Tyr535, Gln536, 
and Gly537 were inserted instead of GluD2 residues Asp542, Tyr543, and Ser544 (HS1) and GluN1 residues 
Thr749, Gly750, Glu751, Leu752, Phe753, Phe754, Arg755, Ser756, and Gly757 instead of GluD2 residues Val761, 
Gly762, Asn763, Thr764, Val765, Ala766, Asp767, Arg768, and Gly769 (HS2). Eight water molecules in the vicin-
ity of the D1–D2 hinge region that would cause steric clash were deleted.
Molecular dynamics simulations. The Schrödinger Software Release 2013–2 (Schrödinger, LLC, New 
York, 2013) and the Protein Preparation Wizard 2013-2 (Epik version 2.4, Impact version 5.9, Prime version 3.2, 
Schrödinger, LLC, New York, 2013)32 were used to prepare protein structures for the MD simulations. All crys-
tallographic waters were kept during the preprocessing step. Missing side chains were added, selenomethionine 
converted to methionine and buffer molecules deleted. The hydrogen bond assignment was done using default 
settings. The tleap program of the Amber 12 package (Case DA, Darden TA, Cheatham III TE, Simmerling CL, 
Wang J, Duke RE, Luo R, Walker RC, Zhang W, Merz KM, Roberts B, Hayik S, Roitberg A, Seabra G, Swails J, 
Götz AW, Kolossváry I, Wong KF, Paesani F, Vanicek J, Wolf RM, Liu J, Wu X, Brozell SR, Steinbrecher T, Gohlke 
H, Cai Q, Ye X, Wang J, Hsieh M-J, Cui G, Roe DR, Mathews DH, Seetin MG, Salomon-Ferrer R, Sagui C, Babin 
V, Luchko Gusarov TS, Kovalenko A & Kollman PA (2012), AMBER 12, University of California, San Francisco) 
was used to create prmtop and prmcrd, topology and coordinate files of the proteins, respectively, with the ff99SB 
force field33. The proteins were neutralised with counter ions. The tool ACPYPE34–36 was used to convert prm-
top and prmcrd to GROMACS format, and GROMACS 5.0.237 was used for periodic box generation, solvation, 
equilibration and MD simulations (Abraham MJ, van der Spoel D, Lindahl E & Hess B (2014) The GROMACS 
development team, GROMACS User Manual Version 5.0.2). All protein structures were solvated in a truncated 
octahedron box with TIP3P water. Equilibration of the systems included minimisation of the solvent, gradual 
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heating from 0 to 300 K in the NVT ensemble and 1 ns simulation at 300 K and 1.01325 bar in the NPT ensemble. 
Finally, production MD runs of 100 ns were carried out. The MD simulations were analysed with VMD 1.9.138.
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